Novartis Cushing's Drug Passes Late-Stage Test
EAST HANOVER, N.J. (TheStreet) -- Novartis (NVS) it will seek regulatory approval by the end of the year for a new drug to treat Cushing's disease based on positive results from a phase III study released Wednesday.
The Novartis drug, SOM230, reduced the level of the stress hormone cortisol in a phase III trial that enrolled patients with Cushing's, a disease in which a benign tumor on the adrenal gland causes the body to produce excess cortisol, the company announced.
Only the higher of two doses of SOM230 met the study's primary endpoint -- normalized levels of cortisol after six months of treatment. SOM230's side effect profile included 39% of patients reporting high blood sugar (hyperglycemia) and 18% reporting diabetes. Other side effects include diarrhea in 58% of patients and nausea reported by 38% of patients. Novartis said most side effects reported were mild to moderate but didn't offer any further details.
Cushing's is a relatively rare disease affecting between 2,000 and 3,000 patients in in the U.S., with equal numbers in Europe. Cushing's patients suffer from severe cardiovascular and metabolic disease that is often fatal. No drugs are currently approved to treat the disorder, although Cushing's patients are typically treated first with radiation or surgery.Corcept Therapeutics (CORT), a small U.S.-based drug maker, is testing its own drug, Corlux, in a phase III study of patients with Cushing's disease. Results from the study are expected in December. Earlier Wednesday, Novartis received FDA approval for Gilenya, the first multiple sclerosis drug administered as a pill. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV